SCHEDULE 13G/A: BlackRock Amends THARIMMUNE Stake Disclosure

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership stake in THARIMMUNE INC as of December 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in THARIMMUNE INC.
• As of December 31, 2025, BlackRock, Inc. beneficially owned 765,829 shares of THARIMMUNE INC common stock.
• This represents 2.2% of the total outstanding class of securities.
• BlackRock, Inc. holds sole voting power and sole dispositive power over all 765,829 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of THARIMMUNE INC.
• BlackRock Institutional Trust Company, National Association, a subsidiary of BlackRock, Inc., is identified as an entity that beneficially owns 5% or greater of THARIMMUNE INC's outstanding shares.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of beneficial ownership by a large institutional investor, indicating a passive stake without any specific positive or negative implications for the issuer's operations or future prospects.

Positives

• BlackRock, a major institutional investor, maintains a stake in THARIMMUNE INC, indicating continued interest.
• The filing confirms the shares are held in the ordinary course of business, not for activist purposes, suggesting stability in the ownership structure.

Negatives

• The reported aggregate beneficial ownership by BlackRock, Inc. of 2.2% is below the 5% threshold, which, while not inherently negative, indicates a relatively small passive stake by the parent entity.

Risks

• No specific risks related to THARIMMUNE INC's operations or financial health are disclosed in this ownership filing; the risks are inherent to holding common stock.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates BlackRock's continued passive investment in THARIMMUNE INC. As one of the world's largest asset managers, BlackRock's holdings are often part of broad index-tracking or diversified investment strategies, rather than a specific strategic move related to THARIMMUNE's industry position. The disclosure of a subsidiary holding over 5% highlights the complex structure of large institutional ownership.

Comparison to Industry Standards

• BlackRock's aggregate 2.2% stake in THARIMMUNE INC is a relatively small passive investment for a major institutional investor, consistent with diversified portfolio management.
• The disclosure of a subsidiary, BlackRock Institutional Trust Company, National Association, holding 5% or greater, is a standard practice for large asset managers like BlackRock when filing Schedule 13G, indicating that while the parent's aggregate might be below 5%, a specific fund or trust managed by a subsidiary has crossed the threshold. This is common for entities like Vanguard, State Street, and Fidelity, which also manage numerous funds.

Related Party Transactions

• The filing identifies BlackRock Institutional Trust Company, National Association, a subsidiary of BlackRock, Inc., as an entity that beneficially owns 5% or greater of THARIMMUNE INC's outstanding shares. This highlights a significant interest by a related entity within the BlackRock corporate structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming no intent to influence control.
• Management: Confirms that a major institutional investor holds a passive stake, not seeking to influence management or control.

Next Steps

• BlackRock, Inc. will continue to monitor its beneficial ownership in THARIMMUNE INC and file further amendments to Schedule 13G as required by SEC regulations if its ownership percentage changes significantly or if it crosses certain thresholds.

Key Dates

Recommendation

This is a routine Schedule 13G filing by a large institutional investor, BlackRock, Inc., disclosing a passive 2.2% stake in THARIMMUNE INC. Such filings typically do not contain information that would warrant a change in investment thesis. The disclosure confirms BlackRock's position as a passive holder, not seeking to influence control. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new fundamental information to alter an existing investment decision.

Keywords

THARIMMUNE INC, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake